Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Dr. Perez Discusses the BOLERO-2 Everolimus Trial

December 14th 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

December 9th 2011

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

December 9th 2011

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

December 9th 2011

Dr. JosÃ© Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

December 9th 2011

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

December 9th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

December 9th 2011

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

December 8th 2011

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

December 8th 2011

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

December 7th 2011

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

December 7th 2011

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial

New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ

December 7th 2011

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Dr. Solin Discusses the DCIS Score Recurrence Test

December 7th 2011

Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test

Gene Signature Identifies Early Versus Late Versus No Recurrence in Hormone Receptor-Positive Breast Cancer

December 7th 2011

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.

Emerging Biomarker Science Presents Practical Questions

December 7th 2011

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

November 2011: Trials in Progress

December 6th 2011

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

Dr. White Discusses Exceptions in the Z11 Trial

December 1st 2011

Dr. Julia White from Community Memorial Hospital Discusses Exceptions in the Z11 Trial